Researchers at the Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, has reported an artificial intelligence (AI) tool, as a “large… Read More »AI responses (“chatbots”) compare favourably against ophthalmic specialists (human) using a “large language model” [LLM] for retinal and glaucoma diseases.
Dear EURETINA Members, A very warm welcome to the March 25th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »March 25th, 2024 “EURETINA-Brief”© Issue No. 288
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).
Researchers at Newcastle University and Sunderland Eye Infirmary, UK, have reported that, to date, there is “no evidence that complement inhibition with any agent improves… Read More »A systematic review on complement inhibitors suggests no evidence to date from functional endpoints in advanced AMD.
Researchers at the Department of Ophthalmology, at The Hebrew University of Jerusalem, have reported a new comprehensive analysis on Best disease patients, aimed to document… Read More »Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 7th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »March 7th, 2024 “EURETINA-Brief”© Issue No. 287
Adverum Biotechnologies (NASDAQ: ADVM) has announced to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional… Read More »Advernum Biotechnologies (NASDAQ: ADVM) has raised $127.5 million to progress gene therapy pipeline.
The MACUSTAR consortium, supported by the Innovative Medicines Initiative, has received a further support of funding from industry partners Bayer, Novartis and Roche, agreed to… Read More »The MACUSTAR consortium on AMD has received a further support of funding of €3M and an extension for work until 2027.
An international consortium of clinical researchers, led by Prof. Robert MacLaren, based in Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, UK, has reported… Read More »An international consortium report the largest, longest and comprehensive natural history study of choroideremia – a rare X-linked degenerative retinopathy.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 14th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »February 14th, 2024 “EURETINA-Brief”© Issue No. 286
